UCB
"UCB is a global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009.
We combine biology and chemistry to make major breakthroughs.
By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
We partner with the leaders in the pharmaceutical industry.
The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners - we play to our strengths and tap into the organisations with greater or complementary strengths."